CathWorks

What CathWorks does

CathWorks is an Israel-originated medical technology company that developed the FFRangio System, an angiography-derived physiology (ADP) platform for assessing coronary artery disease during routine catheterization procedures. The system combines artificial intelligence (computer vision) with resistance-based computational science to derive physiologic FFRangio values from standard 2D angiograms taken at three angles, generating a 3D volumetric model of the entire coronary tree and calculating flow resistance at every point along the vessels and side branches. This eliminates the need for invasive pressure wires, adenosine drug stimulation, and additional procedures, delivering approximately 20% lower radiation exposure and 93% pooled diagnostic accuracy across five prospective studies.

The single-product platform is sold as capital equipment with associated per-procedure or subscription software fees to hospitals and cardiac catheterization labs under multi-year B2B contracts. Pricing is quote-based and not publicly disclosed. CathWorks achieved FDA 510(k) clearance in 2018, CE mark in 2017, Japan PMDA approval in 2019, and EU-MDR approval in 2024; it operates from headquarters in Kfar Saba, Israel, with US commercial operations in Newport Beach, California, and regional offices in Tokyo and Amstelveen. Its clinical evidence base is anchored by the ALL-RISE randomized controlled trial (1,930 patients across 59 sites), published in the New England Journal of Medicine in March 2026, demonstrating non-inferior MACE outcomes versus invasive pressure wire guidance.

CathWorks employs an enterprise field sales motion targeting interventional cardiologists and cath lab administrators, supplemented since 2022 by a co-promotion agreement with Medtronic covering the US, Europe, and Japan. Named institutional customers include Lenox Hill/Northwell, Hackensack Meridian, Lehigh Valley Health Network, VA Long Beach, Stanford, Columbia/NYP, and AdventHealth. Medtronic completed its full acquisition of CathWorks in April 2026 for $585 million, integrating the technology into Medtronic's Cardiovascular Portfolio under the Coronary & Renal Denervation business unit.

Name

CathWorks

Legal name

CathWork Inc. and CathWorks Ltd.

Website

https://cath.works

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

51–100 employees

Short description

CathWorks developed the FFRangio System, an AI and computational platform that derives coronary physiology assessments from routine angiograms for interventional cardiologists and cardiac catheterization labs at hospitals. The company was acquired by Medtronic in April 2026 for $585 million.

Ownership category

akta.pro rank

Product category

Interventional Cardiology Devices

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

Keywords

• Interventional cardiology devices
• Coronary physiology assessment
• Angiography-derived FFR
• Cardiac catheterization software
• AI-powered medical imaging

Headquarters

HQ city

Kfar Saba

HQ country

Israel

HQ region

Middle East

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Capital Equipment and Consumables: CathWorks sells the FFRangio System as a capital medical device with associated consumables and software licensing to hospitals and catheterization labs. The system integrates with existing cath lab infrastructure (boom and PACS). Revenue is generated through initial system placement and ongoing per-procedure or subscription-based software utilization fees.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

CathWorks sells the FFRangio System, a capital medical device that uses AI and computational science to derive fractional flow reserve (FFR) values from standard angiographic images, enabling a non-invasive, full-coronary-tree physiological assessment of coronary artery disease during cardiac catheterization. The system integrates with the cath lab boom, PACS, and hemodynamic systems and is sold to hospitals, health systems, and catheterization labs along with associated consumables and software licensing.

Product overview

CathWorks offers a single unified product—the FFRangio System—which is an angiography-derived physiology (ADP) technology that combines artificial intelligence and computational science to assess coronary artery disease from routine angiograms. The system provides drug-free, wire-free, multi-vessel physiologic assessment, generating FFRangio values across the entire coronary tree. It includes integrated tools such as a virtual pullback curve, Lesion Impact for assessing residual ischemia, and a sizing tool validated against intravascular ultrasound. The FFRangio System has received regulatory clearances including FDA 510(k), CE Mark, Japan PMDA approval, and EU-MDR certification. The company was acquired by Medtronic in April 2026 for $585 million.

Differentiator

Problem solved

Functional benefit

Brands

• FFRangio System: AI-powered angiography-derived fractional flow reserve system that provides physiological assessment of coronary arteries from routine angiograms without the need for invasive pressure wires or drug stimulation.

Products and services

• CathWorks FFRangio System The CathWorks FFRangio System is a capital medical device that uses AI and resistance-based computational science to derive fractional flow reserve (FFR) values from standard angiographic images, providing a non-invasive, full-coronary-tree, three-dimensional physiological assessment of coronary artery disease during cardiac catheterization. It integrates with the cath-lab boom, PACS, and hemodynamic systems and includes tools such as simulated pullback curves, a lesion impact tool, and an integrated sizing tool. It is sold as a system with consumables and software licensing to hospitals and catheterization labs.

Quantifiable outcome

• MACE rate 6.9% vs 7.1% for pressure wire (HR 0.98, p=0.0008) at 1 year in ALL-RISE RCT (1,930 patients)
• +5 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Partnerships

Two partnerships are on record, tiered flagship.

• MedtronicflagshipStrategic or Co-development Partner · 20 April 2026Medtronic completed its acquisition of CathWorks for $585 million in April 2026, following a 2022 co-promotion partnership and strategic investment. Medtronic had held a minority stake in CathWorks since 2018. The acquisition gives Medtronic full ownership of the FFRangio System, integrating it into the Cardiovascular Portfolio under the Coronary & Renal Denervation business unit. The transaction includes potential undisclosed earn-out payments and was expected to be immaterial to Medtronic's FY27 earnings, becoming neutral to accretive thereafter.
• MedtronicflagshipGTM or Marketing Partner · 1 July 2022In July 2022, CathWorks entered a co-promotion agreement with Medtronic for the FFRangio System in the U.S., Europe, and Japan, with a path toward acquisition. The partnership amplified CathWorks' efforts to bring FFRangio benefits to more physicians and patients globally, with Medtronic leveraging its cardiovascular sales force and distribution network to accelerate adoption.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• HeartFlow: Direct competitor offering non-invasive coronary physiology assessment via CT-FFR analysis. HeartFlow targets the same interventional cardiology customer base seeking to eliminate invasive pressure wires, making it the closest direct alternative to FFRangio in coronary physiology, albeit using CT rather than angiography as input.

Broad incumbents

• Philips: Major cardiovascular imaging and physiology incumbent with a broad cath lab, IVUS, and adjacent cardiology product portfolio. Philips competes with FFRangio for cath lab workflow share and physician mindshare across interventional cardiology as part of a much larger CV and imaging franchise.
• Abbott: Established coronary physiology incumbent via its PressureWire FFR product line and broader cardiovascular portfolio. Abbott targets the same interventional cardiologists as CathWorks and competes across both invasive physiology (PressureWire) and adjacent cath lab device categories.
• Boston Scientific: Major cardiovascular device company with coronary physiology products, IVUS, and a broader cath lab portfolio. Boston Scientific competes with CathWorks/FFRangio for hospital cath lab budgets, capital equipment slots, and interventional cardiology customer relationships.
• GE HealthCare: Broad cardiology imaging and informatics provider spanning cath lab, echo, CT, and MR. GE HealthCare offers adjacent imaging analytics and workflow tools that overlap with FFRangio's cath lab use cases, though as part of a much larger enterprise imaging franchise.
• Siemens Healthineers: Major cardiovascular imaging equipment and informatics provider with cath lab angiography systems and AI-driven imaging tools. Siemens competes with FFRangio through its installed base of cath lab equipment and increasingly AI-enabled imaging analytics.

Emerging players

• ACIST Medical Systems: Cath lab-focused medical device company offering FFR and coronary physiology products. ACIST directly competes with FFRangio in the coronary physiology space but has a narrower product portfolio and is more specialized than the broad CV incumbents.
• Opsens (Haemonetics): Maker of the OptoWire FFR pressure wire and related physiology products, now part of Haemonetics. Opsens offers an alternative fiber-optic-based approach to coronary physiology assessment that competes with FFRangio's wire-free, angiography-derived approach in the cath lab.
• Cleerly: AI-driven coronary plaque and imaging analysis company targeting similar interventional cardiology customers. Cleerly applies computational, image-based cardiovascular assessment to coronary CTA — adjacent technology to FFRangio's angiography-derived approach.

Others

• CathVision: Cardiac electrophysiology mapping and recording system provider serving cath labs. Thematically related as cath lab technology, but CathVision focuses on EP procedures rather than coronary physiology — adjacent rather than directly competitive to FFRangio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cathworks/jobs
• Xx.com/cathworks
• Facebookfacebook.com/CathWorksFFRangio

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CathWorks